



Proteomics International

LABORATORIES LTD

ASX/Media Release

28 June 2016

ASX code: PIQ

Board Changes

Proteomics International Laboratories Ltd (ASX: PIQ) (the **Company**) announces that Dr Bill Parker and Mr James Moses have resigned as Directors of the Company.

Dr Parker was a founder of Proteomics International in 2001, and has made a long and significant scientific contribution to PIQ but steps down to ensure that the Board of Directors is of a size and composition that is suited to a company at PIQ's stage of development. Dr Parker will continue to provide guidance to the Proteomics International management team in a consultancy role on terms to be negotiated on an arms' length basis.

Mr Moses provided investor relations services during and subsequent to the Company's IPO. He has resigned due to the pressure of other professional commitments. The Board on behalf of its shareholders expresses their gratitude to Dr Parker and Mr Moses for their valued contribution to PIQ and wish them the very best in their future endeavours.

PIQ is in the process of commercialising its innovative technologies and patented diagnostic IP, and remains focused on developing its pipeline of products and services. The remaining founding Directors, Dr Richard Lipscombe (Managing Director) and Dr John Dunlop (Non-Executive Director), together with Non-Executive Chairman Terry Sweet, will continue to ensure that the Company is positioned to achieve these objectives and realise long term growth for its shareholders.

ENDS

For further information please contact:

Karen Logan
Company Secretary
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

About Proteomics International Laboratories (PILL)

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com